Drug Profile
Oxelumab
Alternative Names: Anti-OX40L - Genentech; huMAb OX40L; OX40L huMab; R4930; RG 4930; RO4989991; Roche 4Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech; Genmab; Roche
- Class Antiasthmatics; Monoclonal antibodies
- Mechanism of Action OX40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic asthma; Allergic rhinitis
Most Recent Events
- 30 Jun 2011 Discontinued - Phase-I for Allergic rhinitis in USA (IV)
- 30 Jun 2011 Discontinued - Phase-II for Allergic asthma in Canada (IV)
- 30 Apr 2011 Roche completes a phase I trial in Allergic rhinitis in USA (NCT01152619)